ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Correction: Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
Daniel H Ahn et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.